VJHemOnc is committed to improving our service to you

EHA 2019 | Gilteritinib prolongs OS in FLT3+ R/R AML: Phase 3 ADMIRAL results

VJHemOnc is committed to improving our service to you

Alexander Perl

Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the results of the Phase III ADMIRAL trial (NCT02421939) of gilteritinib in FLT3+ relapsed/refractory acute myeloid leukemia (AML) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter